StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.03+0.07 (+7.29%)

Close on Nov 18, 2026Market cap $28.59MP/E –Yield –

Inmune Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Inmune Bio's revenue for the twelve months ending Dec 31, 2025 was $50.00K, up 257.1% year over year. For fiscal 2025 it was $50.00K, up 257.1% from the year before. The highest annual figure on record is $374.00K in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$50.00K+257.1%
FY2024Dec 31, 2024$14.00K-91.0%
FY2023Dec 31, 2023$155.00K-58.6%
FY2022Dec 31, 2022$374.00K+106.6%
FY2021Dec 31, 2021$181.00K+1545.5%
FY2020Dec 31, 2020$11.00K–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$50.00K+257.1%
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$14.00K-63.2%
Q4 FY2023Dec 31, 2023$28.00K-71.1%
Q3 FY2023Sep 30, 2023$43.00K-56.1%
Q2 FY2023Jun 30, 2023$46.00K+187.5%
Q1 FY2023Mar 31, 2023$38.00K-76.7%
Q4 FY2022Dec 31, 2022$97.00K-40.5%
Q3 FY2022Sep 30, 2022$98.00K+600.0%
Q2 FY2022Jun 30, 2022$16.00K–
Q1 FY2022Mar 31, 2022$163.00K+3975.0%
Q4 FY2021Dec 31, 2021$163.00K–
Q3 FY2021Sep 30, 2021$14.00K–
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$4.00K–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–

More Inmune Bio figures

See a number that looks wrong?